Randomized comparison of two doses of the anti-PD-1 monoclonal antibody MK-3475 for ipilimumab-refractory (IPI-R) and IPI-naive (IPI-N) melanoma (MEL).
Omid Hamid
Consultant or Advisory Role - Merck
Research Funding - Merck
Caroline Robert
Consultant or Advisory Role - Amgen; Bristol-Myers Squibb; GlaxoSmithKline; Merck; Novartis; Roche
Antoni Ribas
Consultant or Advisory Role - Amgen; Genentech; GlaxoSmithKline; Merck
Stock Ownership - Kite Pharma
Jedd D. Wolchok
Consultant or Advisory Role - Bristol-Myers Squibb; GlaxoSmithKline; MedImmune; Merck
Research Funding - Bristol-Myers Squibb; GlaxoSmithKline; MedImmune; Merck
F. Stephen Hodi
Consultant or Advisory Role - Merck
Research Funding - Merck
Richard Kefford
Consultant or Advisory Role - Merck
Honoraria - Merck
Other Remuneration - Merck
Anthony M. Joshua
Consultant or Advisory Role - Merck
Wen-Jen Hwu
Consultant or Advisory Role - Merck; Novartis
Research Funding - Bristol-Myers Squibb; GlaxoSmithKline; MedImmune; Merck
Tara C. Gangadhar
No relevant relationships to disclose
Amita Patnaik
Research Funding - Merck
Peter Hersey
No relevant relationships to disclose
Jeffrey S. Weber
Consultant or Advisory Role - Merck
Honoraria - Merck
Research Funding - Merck
Richard Wayne Joseph
No relevant relationships to disclose
Kevin Gergich
Employment or Leadership Position - Merck
Stock Ownership - Merck
Xiaoyun (Nicole) Li
Employment or Leadership Position - Merck
Stock Ownership - Merck
Patrick Chun
Employment or Leadership Position - Merck
Stock Ownership - Merck
Scot Ebbinghaus
Employment or Leadership Position - Merck
Stock Ownership - Merck
Soonmo Peter Kang
Employment or Leadership Position - Merck
Adil Daud
Consultant or Advisory Role - Merck; Oncoscience
Research Funding - Merck